Medincell
Medincell, a pioneering biopharmaceutical company headquartered in France, focuses on the development of innovative long-acting injectable therapies. Founded in 2000, the company has made significant strides in the industry, particularly in the fields of mental health and chronic diseases. Medincell's proprietary technology platform, which enables the sustained release of active pharmaceutical ingredients, sets it apart from competitors. With a strong presence in Europe and expanding operations globally, Medincell is committed to addressing unmet medical needs through its core products, including its lead candidate for the treatment of schizophrenia. The company has garnered recognition for its unique approach to drug delivery, positioning itself as a leader in the biopharmaceutical sector. Medincell continues to advance its mission of improving patient outcomes through innovative therapeutic solutions.
DitchCarbon Score
How does Medincell's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medincell's score of 56 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Medincell's reported carbon emissions
In 2024, Medincell reported total carbon emissions of approximately 5,000,000 kg CO2e, with significant contributions from Scope 3 emissions, which accounted for about 4,214,400 kg CO2e from purchased goods and services alone. The breakdown of emissions for 2024 includes 776 kg CO2e from Scope 1, 40,820 kg CO2e from Scope 2 (purchased electricity), and various categories under Scope 3, such as capital goods (438,230 kg CO2e) and business travel (212,750 kg CO2e). In 2023, the company recorded total emissions of about 5,000,000 kg CO2e, with Scope 2 emissions at 12,860 kg CO2e and Scope 3 emissions reaching approximately 5,120,280 kg CO2e, indicating a consistent reliance on indirect emissions sources. Medincell has not disclosed specific reduction targets or initiatives as part of their climate commitments. However, they have consistently reported their emissions across all relevant scopes, demonstrating transparency in their environmental impact. The company is headquartered in France and is committed to addressing its carbon footprint, although specific reduction strategies or pledges have not been outlined.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | 000 |
| Scope 2 | 7,640 | 0,000 | 0,000 | 00,000 | 00,000 | 00,000 |
| Scope 3 | - | - | - | - | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Medincell is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
